Keywords
How to Cite
Abstract
Objective: The present study was designed to explore the combination therapy of lycopene with aliskiren in doxorubicin induced cardiomyopathy.
Methods: Cardiomyopathy was induced in Wistar rats by i.p. administration of Doxorubicin (DOX) (15 mg/kg, single dose). Haemodynamic parameters (Systolic, diastolic blood pressure, Heart rate), heart weight, heart weight/body weight ratio, serum lactate dehydrogenase (LDH), oxidative stress (TBARS) and antioxidant enzymes (Glutathione, SOD and catalase) as well as transmission electron microscopein heart tissue were carried out.
Results: There was significant increase in blood pressure, serum, lactate dehydrogenase (LDH), oxidative stress (TBARS) and significant decrease in heart weight, heart weight/body weight ratio and antioxidant enzymes in cardiomyopathic rats. Combined therapy of lycopene (2 and 4mg/kg) with aliskiren (100 mg/kg) treatment showed pronounced beneficial effecton above parameters.Furthermore lycopene with aliskiren significantly improves the antioxidant defense by increasing reduced glutathione, SOD, catalase, heart size and heart weight/body weight ratio. It is clearly observed from Transmission electron microscopic slides of DOX treated rats, there was swelling of mitochondria with disruption of cristae, rupture of nuclear membrane, condensation and margination of nuclear chromatins which were well protected by lycopene along with aliskiren treatment.
Conclusion: Therefore, combination therapy of lycopene with aliskiren offers better treatment for DOX-induced cardiomyopathy than ALK alone.
References
Sacco G, et al. Cardioprotective effects of zofenopril, a new angiotensin-converting enzyme inhibitor, on doxorubicin-induced cardiotoxicity in the rat. European Journal of Pharmacology 2001; 414: 71-78. http://dx.doi.org/10.1016/S0014-2999(01)00782-8
Luca G, et al. Anthracycline cardiomyopathy in breast cancer patients: synergism with trastuzumab and taxanes. Cardiovascular Toxicology 2007; 7: 67-71. http://dx.doi.org/10.1007/s12012-007-0013-5
Hiona A, et al. Pre-treatment with ACE inhibitor attenuates doxorubicin-induced cardiomyopathy via preservation of mitochondrial function. J Thorac Cardiovac Surg 2011; 142: 396-403. http://dx.doi.org/10.1016/j.jtcvs.2010.07.097
Siveski-Iliskovic N, et al. Probucol promotes endogenous antioxidants and provides protection against adriamycin-induced cardiomyopathy in rats. Circulation 1994; 89: 2829-2835. http://dx.doi.org/10.1161/01.CIR.89.6.2829
Sharma H, et al. Anti-apoptotic potential of rosuvastatin pretreatment in murine model of cardiomyopathy. Int J Cardiol 2011; 150: 193-200. http://dx.doi.org/10.1016/j.ijcard.2010.04.008
Ferreira AL, et al. Doxorubicin as an antioxidant: maintenance of myocardial levels of lycopene under doxorubicin treatment. Free Radic Biol Med 2007; 43: 740-51. http://dx.doi.org/10.1016/j.freeradbiomed.2007.05.002
Myers CE, et al. Adriamycin: the role of lipid peroxidation in cardiac toxicity and tumor response. Science 1977; 197: 165-167. http://dx.doi.org/10.1126/science.877547
Rashikh A, et al. Aliskiren attenuates myocardial apoptosis and oxidative stress in chronic murine model of cardiomyopathy. Biomed Pharmacother 2012; 5: 529-535. http://dx.doi.org/10.1016/j.biopha.2011.11.020
Toko H, et al. Angiotensin II: type 1a receptor mediates Doxorubicin-induced cardiomyopathy. Hypertens Res 2002; 25: 597-603. http://dx.doi.org/10.1291/hypres.25.597
Nazeyrollas P, et al. Effects of amifostine on perfused isolated rat heart and on acute doxorubicin-induced cardiomyopathy. Cancer Chemother Pharmacol 1999; 43: 227-32. http://dx.doi.org/10.1007/s002800050888
Liu X, et al. Melatonin as an effective protector against doxorubicin-induced cardiomyopathy. Am J Physiol: Heart Cir Physiol 2002; 283: H254-63. http://dx.doi.org/10.1152/ajpheart.01023.2001
Xu Z, et al. Ghrelin prevents doxorubicin-induced cardiotoxicity through TNF-alpha/NF-kB pathways and mitochondrial protective mechanisms. Toxicol 2008; 247: 133-138. http://dx.doi.org/10.1016/j.tox.2008.02.018
Soga M, et al. Effects of angiotensin II receptor blocker in daunorubicin-induced cardiomyopathic rats. Intern J Cardiol 2006; 110: 378-385. http://dx.doi.org/10.1016/j.ijcard.2005.08.061
Hollenberg NK, et al. Pathways for angiotensin II generation in intact human tissue: evidence from comparative pharmacological interruption of the renin system. Hypertens 1998; 32: 387-92. http://dx.doi.org/10.1161/01.HYP.32.3.387
Young DS. Effects of drugs on clinical laboratory tests. Washington: AACC press, 1990; 120-22.
Stahl W, Sies H. Physical quenching of singlet oxygen and cis-trans isomerization of carotenoids. Annals New York Academy of Science 1993; 691: 10-19. http://dx.doi.org/10.1111/j.1749-6632.1993.tb26153.x
Di Mascio P, et al. Lycopene as the most efficient biological carotenoid singlet oxygen quencher. Arch Biochem Biophys 1989; 274: 532-538. http://dx.doi.org/10.1016/0003-9861(89)90467-0
Ojha S, et al. Cardioprotective effect of lycopene against isoproterenol-induced myocardial infarction in rats. Human and Experimental Toxicology 2013; 32: 492-503. http://dx.doi.org/10.1177/0960327112454890
Pennathur S, et al. Potent antioxidative activity of lycopene: A potential role in scavenging hypochlorous acid. Free Radic Biol Med 2010; 49(2): 205-13. http://dx.doi.org/10.1016/j.freeradbiomed.2010.04.003
Ferreira AL, et al. Tomato-oleoresin supplement prevents doxorubicin-induced cardiac myocyte oxidative DNA damage in rats. Mutat Res 2007; 631: 26-35. http://dx.doi.org/10.1016/j.freeradbiomed.2010.04.003
Ohkawa H, et al. Assay for lipid peroxides in animal tissues by thiobarbituric acid reaction. Anal Biochem 1979; 95: 359-64. http://dx.doi.org/10.1016/0003-2697(79)90738-3
Sedlack J, Lindsay RH. Estimation of total, protein bound and non-protein bound sulfhydryl groups in tissue with Ellman’s reagent. Anal Biochem 1968; 25: 192-205. http://dx.doi.org/10.1016/0003-2697(68)90092-4
Marklund S, Marklund G. Involvement of the superoxide anion radical in the autoxidation of pyrogallol and a convenient assay for superoxide dismutase. Eur J Biochem 1974; 47: 469-74. http://dx.doi.org/10.1111/j.1432-1033.1974.tb03714.x
Clairbome A. Assay of catalase. In: Greenwald RA, editor. Handbook of Methods of Oxygen Free Radical Research. Boca Raton: CRC Press, 1985; 283-84.
Singal PK, Iliskovic N. Adriamycin cardiomyopathy. N Engl J Med 1998; 339: 900-905. http://dx.doi.org/10.1056/NEJM199809243391307
Pathan RA, et al. Naproxen aggravates Doxorubicininduced cardiomyopathy in rats. Indian J Pharmacol 2010; 42: 44-49. http://dx.doi.org/10.4103/0253-7613.62411
Zhu W, et al. MAPK superfamily plays an important role in daunomycin-induced apoptosis of cardiac myocytes. Circ 1999; 100: 2100-07. http://dx.doi.org/10.1161/01.CIR.100.20.2100
Goto T, Takase H, Toriyama T. Circulating concentrations of cardiac proteins indicate the severity of congestive heart failure. Heart 2003; 89: 1303-7. http://dx.doi.org/10.1136/heart.89.11.1303
Singh BK, et al. Diclofenac sodium, a nonselective nonsteroidal anti-inflammatory drug aggravates doxorubicin-induced cardiomyopathy in rats. J Cardiovascul Pharmacol 2010; 55; 139-14. http://dx.doi.org/10.1097/FJC.0b013e3181c87e17
Yilmaz S, et al. Protective effect of lycopene on adriamycin-induced cardiotoxicity and nephrotoxicity. Toxicology 2006; 218: 164-171. http://dx.doi.org/10.1016/j.tox.2005.10.015
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
Copyright (c) 2015 Vinay Kumar, Surama Chauhan, K. Nagarajan , Bhulan Kumar Singh